WIDE RANGE OF INTERMEDIATE PRODUCTS FOR THE PHARMACEUTICAL INDUSTRY - BACK TO EUROPE

Pharma

We offer more than just a product, we provide future-oriented solutions with the following intermediate products.

Bioselect^® (high-purity guanidine salts) for biotechnological, diagnostic and pharmaceutical applications.
Cyanamide as an anti-worm agent for human and veterinary medicine.
Dicyandiamide as a synthesis building block for active pharmaceutical ingredients (API's), e.g. for the production of metformin (medication against type II diabetes).
NITRALZ^® (nitriles) for the API production of various medicines for the treatment of e.g. hypertension, heart disease, HIV and cancer.
NIGU^® (Nitroguanidine) as an intermediate in the synthesis of pharmaceuticals and veterinary products
Thiourea as a raw material for the production of various human medicines, e.g. for the treatment of Parkinson's disease.
Creavitalis^® (Creatine Monohydrate) raw material for health applications for vitality and well-being by supporting energy metabolism.

Product
News and Stories

Innovation, sustainability, health & safety play a fundamental role.

We have more than 60 years of experience in the development and manufacture of advanced, high-quality specialty and intermediate products for pharmaceutical applications.

In cooperation with you, we develop tailor-made solutions, such as customized buffer solutions based on guanidine thiocyanate and guanidine hydrochloride. Thanks to our many years of experience and our wide range of technologies, we can offer you a comprehensive service.

Due to our deep market and customer understanding and our stable supply chain, we are able to offer reliable and consistently high quality "Made in Germany" products.

Labor Reagenzglas Pflanzen Pipette Nahaufnahme

Bioselect®

Toll manufacturing

Cyanamide

Dicyandiamide

Nitralz®

Thiourea

Creavitalis®

Pharma Flyer

PDF

Pharma Flyer

2 MB

Act now.

Act together.

The Alzchem Group forms a unique production network. Such an interconnected system conserves resources, saves energy, reduces emissions, transport costs and uses the synergies of an integrated infrastructure.

News and Stories

Alzchem, Corporate News

Management Board contracts extended

At its December meeting, the Supervisory Board of Alzchem Group AG took an important step toward ensuring the continuity and future growth of the company: it was decided to extend the employment contracts of CEO Andreas Niedermaier and CFO Andreas Lösler, which were due to expire at the end of 2026, ahead of schedule.

Ad-Hoc, Alzchem

Alzchem Group AG Announces Share Buyback

The Management Board of Alzchem Group AG, with the approval of the Supervisory Board, has resolved to repurchase up to 70,000 shares of the company via the stock exchange over a period of up to 12 months, for a total purchase price of up to EUR 10 million (excluding ancillary acquisition costs).

Alzchem, Corporate News

Alzchem Group AG approves growth investments

Alzchem Group AG, a globally active specialty chemicals company, has approved a comprehensive investment program to achieve additional profitable growth and further strengthen its market position. The focus is particularly on the areas of sports, food and health. To this end, a total of around EUR 120 million is to be invested in the construction of an increasingly automated production plant for creatine and its precursors, as well as in the upstream infrastructure.

Ad-Hoc, Alzchem

Investment program worth around EUR 120 million

Alzchem Group AG has adopted a comprehensive investment program for further capacity expansion in creatine products.

Alzchem, Human Nutrition, Press release

Creapure^® Continues Successful Collaboration with HYROX

Alzchem Group, manufacturer of the premium creatine Creapure®, and HYROX, the world’s leading fitness event series, are extending their partnership for the 2025/2026 season.